SCHEMBL611982

SCHEMBL611982

Cc1ccc(-c2nc3ccc(C)nn3c2CC(=O)Nc2cc(C)no2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.44
ALDH1A1 P00352 1/20 0.44
TSPO P30536 5/20 0.42
KDM4E B2RXH2 2/20 0.39
HSD17B10 Q99714 2/20 0.39
GABRA1 P14867 2/20 0.39
GABRB2 P47870 2/20 0.39
LMNA P02545 1/20 0.39
ALB P02768 1/20 0.39
CYP3A4 P08684 1/20 0.39
CHRM1 P11229 1/20 0.39
HPGD P15428 1/20 0.39
GABRB1 P18505 1/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA3 P34903 1/20 0.39
ADRA1A P35348 1/20 0.39
OPRK1 P41145 1/20 0.39
HTR2B P41595 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL610176 0.86 GAPDH (0.54) ROCK1SMN1; SMN2ALDH1A1TSPOKDM4E
SCHEMBL608415 0.84 GAA (0.51) SMN1; SMN2ALDH1A1TSPOKDM4EHSD17B10
SCHEMBL611077 0.84 TSPO (0.40) TSPOKDM4EHSD17B10GABRA1GABRB2
SCHEMBL612415 0.81 GAA (0.46) TSPOKDM4EHSD17B10GABRA1GABRB2
SCHEMBL610335 0.79 POLB (0.55) ROCK1SMN1; SMN2TSPOKDM4EHSD17B10
SCHEMBL612654 0.79 NPC1 (0.47) ROCK1SMN1; SMN2ALDH1A1KDM4ELMNA
SCHEMBL610485 0.79 GABRA1 (0.48) TSPOKDM4EHSD17B10GABRA1GABRB2
SCHEMBL611044 0.78 TSPO (0.43) ALDH1A1TSPOKDM4EHSD17B10GABRA1
SCHEMBL612631 0.78 KMT2A (0.53) SMN1; SMN2ALDH1A1TSPOKDM4EHSD17B10
SCHEMBL612231 0.78 KMT2A (0.46) SMN1; SMN2ALDH1A1TSPOKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120040979-A1 IMIDAZO[1,2-B]PYRIDAZINES, PROCESSES, USES, INTERMEDIATES AND COMPOSITIONS FALCO JOSE LUIS (ES) 2012-02-16 US claimed
EP-2010536-B1 IMIDAZO [1, 2-B]PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS FERRER INT (ES) 2010-06-16 EP claimed
US-20090176788-A1 Imidazo[1,2-B]Pyridazines, Processes, Uses, Intermediates and Compositions FERRER INTERNACIONAL, S.A. (ES) 2009-07-09 US claimed
EP-2010536-A1 IMIDAZO [1, 2-B]PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS Ferrer Internacional, S.A. (ES) 2009-01-07 EP claimed
EP-1845098-A1 Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands FERRER INTERNACIONAL, S.A. (ES) 2007-10-17 EP claimed
WO-2007110437-A1 IMIDAZO [1, 2-B] PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS FERRER INTERNACIONAL, S.A. (ES) 2007-10-04 WO claimed
US-8993562-B2 Imidazo[1,2-b]pyridazines, processes, uses, intermediates and compositions FERRER INTERNACIONAL, S.A. (ES) 2015-03-31 US disclosed
US-8153789-B2 Imidazo[1,2-b]pyridazines, processes, uses, intermediates and compositions FERRER INTERNACIONAL, S.A. (ES) 2012-04-10 US disclosed
US-20120040979-A1 IMIDAZO[1,2-B]PYRIDAZINES, PROCESSES, USES, INTERMEDIATES AND COMPOSITIONS FALCO JOSE LUIS (ES) 2012-02-16 US disclosed
EP-2010536-B1 IMIDAZO [1, 2-B]PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS FERRER INT (ES) 2010-06-16 EP disclosed
US-20090176788-A1 Imidazo[1,2-B]Pyridazines, Processes, Uses, Intermediates and Compositions FERRER INTERNACIONAL, S.A. (ES) 2009-07-09 US disclosed
EP-2010536-A1 IMIDAZO [1, 2-B]PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS Ferrer Internacional, S.A. (ES) 2009-01-07 EP disclosed
EP-1845098-A1 Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands FERRER INTERNACIONAL, S.A. (ES) 2007-10-17 EP disclosed
WO-2007110437-A1 IMIDAZO [1, 2-B] PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS FERRER INTERNACIONAL, S.A. (ES) 2007-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176788-A1 Imidazo[1,2-B]Pyridazines, Processes, Uses, Intermediates and Compositions GABRA5, GABRA1, GABRA2 ROCK1 2124/4885SMN1; SMN2 581/4885ALDH1A1 976/4885
US-20120040979-A1 IMIDAZO[1,2-B]PYRIDAZINES, PROCESSES, USES, INTERMEDIATES AND COMPOSITIONS GABRA5, GABRA1, GABRA2 ROCK1 2124/4885SMN1; SMN2 581/4885ALDH1A1 976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.